paprizumab + cisplatin + fluorouracil

This is a combination regimen consisting of three drugs: - **Paprizumab** is an investigational monoclonal antibody. There is limited public information available about its specific target or mechanism of action. - **Cisplatin** is a platinum-based chemotherapy agent that forms DNA crosslinks and inhibits DNA synthesis and function, leading to apoptosis in rapidly dividing cells. - **Fluorouracil (5-FU)** is an antimetabolite chemotherapy drug that inhibits thymidylate synthase, disrupting DNA synthesis and cell division. This combination would be considered an experimental regimen likely under investigation for cancer treatment. Cisplatin and fluorouracil are commonly used together in the treatment of various solid tumors (such as head and neck, esophageal, gastric cancers), often with other agents or investigational drugs.